What are the most common side effects of ABROCITINIB?

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for ABROCITINIB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Is ABROCITINIB the same as CIBINQO?

CIBINQO is a brand name for ABROCITINIB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

ABROCITINIB

Q: What is ABROCITINIB used for?

ABROCITINIB (brand name CIBINQO) is a JAK Inhibitor indicated for 1 INDICATIONS AND USAGE CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics.

Q: How does ABROCITINIB work?

ABROCITINIB works through the following mechanism: 12.1 Mechanism of Action CIBINQO is a Janus kinase (JAK) inhibitor. Abrocitinib reversibly inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site. In a cell-free isolated enzyme assay, abrocitinib was selective for JAK1 over JAK2 (28-fold), JAK3 (>340-fold), and tyrosine kinase (TYK) 2 (43-fold), as well as the broader kinome. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known. Both the parent compound and the active metabolites inhibit JAK1 activity in vitro with similar levels of selectivity..

JAK Inhibitor

Brand names: CIBINQO, Cibinqo

Oral

Mechanism of Action

12.1 Mechanism of Action CIBINQO is a Janus kinase (JAK) inhibitor. Abrocitinib reversibly inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site. In a cell-free isolated enzyme assay, abrocitinib was selective for JAK1 over JAK2 (28-fold), JAK3 (>340-fold), and tyrosine kinase (TYK) 2 (43-fold), as well as the broader kinome. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known. Both the parent compound and the active metabolites inhibit JAK1 activity in vitro with similar levels of selectivity.

Indications

1 INDICATIONS AND USAGE CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory

moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products

including biologics

or when use of those therapies is inadvisable. CIBINQO is a Janus kinase (JAK) inhibitor indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory

moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products

including biologics

Contraindications

• 4 CONTRAINDICATIONS CIBINQO is contraindicated in patients taking antiplatelet therapies
• except for low-dose aspirin (≤81 mg daily)
• during the first 3 months of treatment [see Warnings and Precautions (5.6)
• Drug Interactions (7.2)
• and Clinical Pharmacology (12.2) ]. Antiplatelet therapies except for low-dose aspirin (≤81 mg daily)

FDA Warnings

5 WARNINGS AND PRECAUTIONS • Laboratory Abnormalities : Laboratory monitoring is recommended due to potential changes in platelets, lymphocytes, and lipids
1 Serious Infections The most frequent serious infections reported in clinical studies with CIBINQO for atopic dermatitis were herpes simplex, herpes zoster, and pneumonia [see Adverse Reactions (6
Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving JAK inhibitors used to treat inflammatory conditions
Avoid use of CIBINQO in patients with active, serious infection including localized infections

Known Side Effects

8 documented side effects by frequency

Drug Not Working

>10%

Condition Worsened

>10%

Itching

1-10%

Rash

1-10%

Nausea

1-10%

Headache

0.1-1%

Fatigue

0.1-1%

Dizziness

0.1-1%

Community Discussions

7 Reddit threads analysed for ABROCITINIB

Overall Sentiment

Mixed

Comparison Threads

Avg Post Score

9 upvotes

Most discussed side effects in community

Itching (1)

Patient Experiences (r/pharmacy, r/AskDocs & more)

Abrocitinib (Jak Inhibitor) Works

Recently started taking a new drug through a clinical trial called Abrocitinib (Made by Pfizer), it is an oral tablet once a day and from what my doctors have said it is comparable and even slightly more effective for people than Dupixent. I wanted to share my results, I have had severe eczema for 7

r/eczema35384y ago

Jak Inhibitor Trial Abrocitinib - 2 Years

I've given a few updates on the trial I'm in for Abrocitinib over the past couple of years - thought I'd round it out now the trial is coming to an end. I think I last posted around the 18 month mark and said I felt the effects were wearing off and some mild eczema had returned. I'm happy to say th

r/eczema1475y ago

On Dupilumab 2 months - my skin is oily?!

I've had full body eczema since about 18 years old. I can't really remember what my skin was like before then. Managing my eczema has been such a big part of my adult life. But after 2 months on dupixent I feel like my skin has never been as smooth.. or as oily! It's honestly taking my brain a whil

r/eczema722y ago

Itching

Abrocitinib and its Articles

Quick rant here! Because It’s getting annoying and frustrating that they always hype up the new drugs for eczema sufferers for example, the JAK inhibitors, and I’m so happy to read the results but they never want to discuss the adverse side effects. They always want to say it’s mild and that they’re

r/eczema325y ago

Abrocitinib/Cibinqo Discontinuation - 2 weeks

This might be helpful for some of you who discontinue Cibinqo. I've been on it 5 years but unfortunately the trial ended here in Australia and the medication has yet to be approved. I had amazing results on it - next to no eczema/AD for the 5 years. I took my last pill 2 weeks ago and the flare has

r/eczema272y ago

Has anyone participated in Pfizer Abrocitinib clinical trials?

I've just read the article https://www.businesswire.com/news/home/20191012005003/en/ And I was wondering if anyone tried this? Were there any bad side effects? I found some old topics of some participants, maybe there's an update to that. Tbh all the topics made me cry, since nothing helps me and e

r/eczema246y ago

people's experience with abrocitinib, upadacitinib and tralokinumab?

These drugs have just been approved in UK by NHS as pills and in the tests for UK they basically cured eczema, any of you guys from other countries tried this?

r/eczema2113y ago

Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.

Primary sources

Every figure on this page links back to its primary source. See data sources for full provenance.

DailyMed FDA label search → ABROCITINIB openFDA label JSON → ABROCITINIB FAERS adverse-event reports → ABROCITINIB ClinicalTrials.gov → completed Phase 2+ trials of ABROCITINIB

Compare With

20 available comparisons

Formulations

Dosage Forms

Tablet

Route

Oral